Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare. The fourth-leading cause of death is drug side effects, and drugs only work half the time, says Hrusovsky. He believes that if you can personalize the drugs, you have an opportunity to improve the whole pharmaceutical industry. Quanterix is developing technology that will digitize how they see into blood, and help to see disease long before there are symptoms. Rocket science is being deployed into the blood, says Hrusovsky. He says that if you can see biomarkers and incorporate into fitbits, it can really help improve health.

Share:
More In Science
Trump Administration to Roll Back Obama-Era Methane Rule
The new proposal, an effort to reverse regulations put in place under President Obama, would — if enacted — eliminate requirements that oil and gas producers inspect for, and repair, methane leaks from their wells, pipelines, and manufacturing facilities.
Climate Change Is Now Part of Medical Education
Dr. Mona Sarfaty, the director of the Medical Society's consortium on climate and health, details how the changing climate requires a change in the way future doctors are taught about public health.
Load More